Navigation Links
QLT announces first quarter 2008 Visudyne(R) sales
Date:4/21/2008

VANCOUVER, April 21 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of US$36.5 million for the quarter ended March 31, 2008. This represents a decrease of 40.4% over sales in the first quarter of 2007. Sales in the U.S. were $9.3 million, up 10.6% from the prior-year first quarter, while sales outside the U.S. were $27.2 million, down 48.5% from the prior year. The drop in Visudyne sales was primarily due to the approval and reimbursement in Europe of alternative therapeutics for age-related macular degeneration.

QLT will release its full financial results on Friday, April 25, 2008, at 7:30 a.m. ET.

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne and Eligard(R) and future product opportunities. For more information, visit our web site at http://www.qltinc.com.

Conference call information

QLT Inc. will hold an investor conference call to discuss first quarter 2008 results on Friday, April 25 at 8:30 a.m. ET (5:30 a.m. PT). The call will be broadcast live via the Internet at http://www.qltinc.com. To participate on the call, please dial 1-800-319-4610 (North America) or 604-638-5340 (International) before 8:30 a.m. ET. A replay of the call will be available via the Internet and also via telephone at 1-800-319-6413 (North America) or 604-638-9010 (International), access code 7157, followed by the "#" sign.

A full explanation of how QLT determines and recognizes revenue resulting from Visudyne sales is contained in the financial statements contained in the periodic reports on Forms 10-Q and 10-K, under the heading "Significant Accounting Policies - Revenue Recognition." Visudyne sales are product sales by Novartis under its agreement with QLT.

QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.

Atrigel is a registered trademark of QLT USA, Inc.

Visudyne is a registered trademark of Novartis AG.

Eligard is a registered trademark of Sanofi-aventis.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

The Visudyne(R) sales figures in this press release are preliminary and unaudited and are not a complete disclosure of our quarterly financial results.

CONTACT: QLT Inc.: Vancouver, Canada, Therese Hayes, Telephone: (604) 707-7000 or 1-800-663-5486, Fax: (604) 707-7001; The Trout Group: New York, USA, Brandon Lewis, Telephone: (646) 378-2915 or Marcy Strickler, Telephone: (646) 378-2927


'/>"/>
SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Breckenridge Announces Approval of Generic Activella(R)
2. Accenx Technologies Announces New Leadership in Sales and Marketing Division
3. VNUS Medical Technologies, Inc. Announces the Hiring of Don Todd as Vice President of Marketing
4. CardiacAssist, Inc. Announces Five New TandemHeart Centers of Excellence
5. HeartWare Announces Move to an Expanded, Upgraded Manufacturing Facility
6. GHX Announces 2008 Best In Class Award Winners
7. AtriCure Announces Web Cast and Conference Call of First Quarter 2008 Financial Results
8. Huifeng Bio-Pharmaceutical (HFGB) Announces Participation in the 59th PHARMCHINA Expo
9. Zimmer Announces New Compliance Model
10. The Alliance for Lupus Research Announces 2008 Grantees
11. TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... , ... June 28, 2017 , ... With the onset of long work hours and ... fractures due to falls at work and at home will only continue to grow unless ... are not following proper safety procedures, a fall at work or home can lead to ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... technology makes it possible to see through objects, has announced the winners of ... consumer apps with its fully programmable, Raspberry Pi-enabled 3D sensor, Walabot . ...
(Date:6/28/2017)... ... , ... As we celebrate our nation’s independence, many Americans will gather around ... time to celebrate National Hot Dog Month. The National Hot Dog and Sausage ... 4th alone and while they enjoy many different kinds of hot dogs, research commissioned ...
(Date:6/28/2017)... ... 2017 , ... Quorum Health announced that Robert A. Vento has been appointed ... Maher was promoted to COO of QHR. , A national search was ... and CEO in December 2016. , “I’m pleased to announce these ...
(Date:6/28/2017)... ... June 28, 2017 , ... The parent company ... in employee engagement. Omaha-based C&A Industries, a national leader in staffing and ... in North America for 2017. The annual award, issued by Achievers, ...
Breaking Medicine News(10 mins):
(Date:6/27/2017)... , June 27, 2017  Therapix Biosciences Ltd. (Nasdaq: ... company specializing in the development of cannabinoid-based drugs, today ... Market Opening Bell in New York, NY ... of its initial public offering (IPO) of American Depository ... March 2017. Dr. Elran Haber, Ph.D., Chief ...
(Date:6/27/2017)... BEACH, Calif. , Jun 27, 2017   NuEyes ... a round of funding to fuel its growth in helping ... ODG (Osterhout Design Group), the leading developer of ... which NuEyes technology sits. The undisclosed funding amount ... venture capital firm, Arab Angel, with offices in ...
(Date:6/20/2017)... and LAGUNA HILLS, Calif. , June ... new data that validate the use of MMprofiler with ... with multiple myeloma (MM). In a poster presentation at ... Association (EHA) in Madrid, Spain , ... for identifying high-risk elderly patients. In ...
Breaking Medicine Technology: